145 related articles for article (PubMed ID: 33610500)
1. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Gómez García LM; Escudero A; Mestre C; Fuster Soler JL; Martínez AP; Vagace Valero JM; Vela M; Ruz B; Navarro A; Fernández L; Fernández A; Leivas A; Martínez-López J; Ferreras C; De Paz R; Blanquer M; Galán V; González B; Corral D; Sisinni L; Mirones I; Balas A; Vicario JL; Valle P; Borobia AM; Pérez-Martínez A
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):328-337.e1. PubMed ID: 33610500
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia.
Muñoz Builes M; Vela Cuenca M; Fuster Soler JL; Astigarraga I; Pascual Martínez A; Vagace Valero JM; Tong HY; Valentín Quiroga J; Fernández Casanova L; Escudero López A; Sisinni L; Blanquer M; Mirones Aguilar I; González Martínez B; Borobia AM; Pérez-Martínez A
BMJ Open; 2020 Jan; 10(1):e029642. PubMed ID: 31919123
[TBL] [Abstract][Full Text] [Related]
3. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A
Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
6. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
8. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
9. [Observation on the efficacy of consolidation chemotherapy combined with allogeneic natural killer cell infusion in the treatment of low and moderate risk acute myeloid leukemia].
Wang CJ; Huang XJ; Gong LZ; Jia JS; Liu XH; Wang Y; Yan CH; Chang YJ; Zhao XS; Shi HX; Lai YY; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):812-817. PubMed ID: 31775478
[No Abstract] [Full Text] [Related]
10. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.
Leivas A; Perez-Martinez A; Blanchard MJ; Martín-Clavero E; Fernández L; Lahuerta JJ; Martinez-Lopez J
Oncoimmunology; 2016; 5(12):e1250051. PubMed ID: 28123890
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
12. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
Fernández L; Leivas A; Valentín J; Escudero A; Corral D; de Paz R; Vela M; Bueno D; Rodríguez R; Torres JM; Díaz-Almirón M; López-Collazo E; Martinez-Lopez J; Pérez-Martínez A
Transfusion; 2018 Jun; 58(6):1340-1347. PubMed ID: 29542132
[TBL] [Abstract][Full Text] [Related]
13. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Fujisaki H; Kakuda H; Shimasaki N; Imai C; Ma J; Lockey T; Eldridge P; Leung WH; Campana D
Cancer Res; 2009 May; 69(9):4010-7. PubMed ID: 19383914
[TBL] [Abstract][Full Text] [Related]
14. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy with double-bright (CD56
Silla L; Valim V; Pezzi A; da Silva M; Wilke I; Nobrega J; Vargas A; Amorin B; Correa B; Zambonato B; Scherer F; Merzoni J; Sekine L; Huls H; Cooper LJ; Paz A; Lee DA
Br J Haematol; 2021 Dec; 195(5):710-721. PubMed ID: 34490616
[TBL] [Abstract][Full Text] [Related]
16. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.
Ahmadvand M; Barough MS; Barkhordar M; Faridfar A; Ghaderi A; Jalaeikhoo H; Rajaienejad M; Majidzadeh K; Ghavamzadeh A; Sarrami-Forooshani R
BMC Cancer; 2023 Nov; 23(1):1090. PubMed ID: 37950209
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
18. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.
Ciurea SO; Schafer JR; Bassett R; Denman CJ; Cao K; Willis D; Rondon G; Chen J; Soebbing D; Kaur I; Gulbis A; Ahmed S; Rezvani K; Shpall EJ; Lee DA; Champlin RE
Blood; 2017 Oct; 130(16):1857-1868. PubMed ID: 28835441
[TBL] [Abstract][Full Text] [Related]
20. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]